Pharmacokinetics infliximab

Pharmacokinetics Infliximab is infused intravenously over at least two hours. It distributes in the vascular compartment, and has a half-life of 9.5 days. Its metabolism and elimination have not been described. 

Pharmacodynamics and Pharmacokinetics of mAbs Muromonab CD-3 Pharmacokinetics Basiliximab Pharmacokinetics Trastuzumab Pharmacokinetics Infliximab Pharmacokinetics Rituximab Pharmacokinetics Palivizumab Pharmacokinetics Recommendations for Future Study References... 

Pharmacokinetics A study of single IV infusions of 3 to 20 mg/kg in Crohn disease or RA patients showed a linear relationship between the dose and the maximum serum concentration. The volume of distribution at steady state was independent of dose and indicated that infliximab was distributed primarily within the vascular compartment. The median terminal half-life of infliximab ranged between 8 to 9.5 days. 

D. Pharmacokinetics and Clinical Use Sulfasalazine, hydroxychloroquine, methotrexate, cyclosporine, penicillamine and leflunomide are given orally. Infliximab and etanercept are given by injection. Gold compounds are available for parenteral use (gold sodium thiomalate and au-rothioglucose) and for oral administration (auranofin). 

Hepatic or renal insufficiency does not significantly alter the pharmacokinetics of CP (194). Since immunosuppressive activity resides exclusively in the metabolites of CP (i.e., phosphoromide mustard and acrolein), pharmacokinetics are not predicted by the parent compound. Correlations between CP pharmacokinetics and pharmacodynamics are difficult to demonstrate. Measuring the metabolites is technically difficult (211). Drug interaction with other cytotoxic agents may increase neutropenia. One case report found the combination of CP plus infliximab was more likely to cause T-cell lymphopenia than either agent alone (212). 

All three drugs appear to have linear pharmacokinetics (296). A loading dose of two treatments two weeks apart seems important. In addition, a similar loading dose schedule was beneficial in using adalimumab for Crohn s disease (278). Autoantibodies can develop against these agents, especially infliximab (280,297). 

---